Literatur
- 01
Den Elzen WP .
van Manen JG .
Boeschoten EW .
et al .
The effect of single and repeatedly high concentrations of C-reactive protein on cardiovascular
and non-cardiovascular mortality in patients starting with dialysis.
Nephrol Dial Transplant.
2006;
21 (6)
1588-1595
- 02
Fishbane S .
Berns JS .
Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin.
Kidney Int.
2005;
68 (3)
1337-1343
- 03
Müller HJ .
et al .
J Am Soc Nephrol.
2006;
17
579A
- 04
Müller HJ .
et al .
J Am Soc Nephrol.
2007;
18
699A
- 05
Wanner C .
Krane V .
März W .
et al .
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
N Engl J Med.
2005;
353(3)
238-248
- 06
Zimmermann J .
Herrlinger S .
Pruy A .
et al .
Inflammation enhances cardiovascular risk and mortality in hemodialysis patients.
Kidney Int.
1999;
55 (2)
648-658
01 Correction of Hemoglobin and Outcomes in Renal Insufficiency
02 Cardiovascular risk Reduction by Early Anemia Treatment with Epoetin
